Head-to-head evidence
Emraclidine vs NTX-253
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Schizophrenia
Shared mechanism: Muscarinic M4 receptor · full Schizophrenia pipeline
Emraclidine
Developed by Pfizer and partners
NCT05227703 · Phase 2 · completed
Participants were randomly assigned to emraclidine 15 mg, emraclidine 30 mg, or matching placebo and were double-blinded, with 130–131 participants per group. The primary clinical endpoint was not met: the Week 6 PANSS comparison was nonsignificant for both 15 mg versus placebo (p=0.2925) and 30 mg versus placebo (p=0.3914).
Next expected readout: February 2028 · NCT07145918 (registry estimate)
NTX-253
Developed by Neurosterix Pharma Sàrl
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Emraclidine's landscape · NTX-253's landscape